Express Pharma Granules India gets licence from DRDO to manufacture and market COVID-19 drug 2-DG

Granules India said on Thursday that it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

“Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.

The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.

Medically Speaking Team

Recent Posts

One Sleepless Night Can Weaken Your Immunity and Trigger Inflammation

Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…

1 day ago

Thick Heart Syndrome: A Silent Threat to Millions in India

Heart disease remains one of the leading causes of death worldwide, and in India, cardiovascular…

1 day ago

Delhi Sees Surge in H1N1 and Influenza B Cases

Delhi is witnessing a sharp rise in flu cases, particularly Influenza B and H1N1 (commonly…

1 day ago

Woman Dies During MRI Scan Due to Medical Negligence

In early February 2025, a tragic incident occurred in Eluru, Andhra Pradesh, where a 61-year-old…

1 day ago

Holi and Eye Safety: Protect Your Vision During Festivities

Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…

2 days ago

FDA Recalls Popular Skincare Products Over Cancer-Causing Chemical

In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…

2 days ago